ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML Trademark

Trademark Overview

On Thursday, November 30, 2017, a trademark application was filed for ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML with the United States Patent and Trademark Office. The USPTO has given the ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML trademark a serial number of 87703113. The federal status of this trademark filing is REGISTERED as of Tuesday, September 22, 2020. This trademark is owned by FIDELIS PHARMACEUTICALS LLC. The ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, buprenorphine extended release injectable suspension to provide analgesia for laboratory animals
ethiqa xr (buprenorphine extended-release injectable suspension) 1.3 mg/ml

General Information

Serial Number87703113
Word MarkETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML
Filing DateThursday, November 30, 2017
Status700 - REGISTERED
Status DateTuesday, September 22, 2020
Registration Number6158527
Registration DateTuesday, September 22, 2020
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 18, 2018

Trademark Statements

Description of MarkThe mark consists of the literal elements "ETHIQA XR", stylized, with the left-hand portion of the "X" enhanced by three stippled outlines of varying shading. At the below are the literal elements "(BUPRENORPHINE EXTENDED RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML".
Goods and ServicesPharmaceutical preparations, namely, buprenorphine extended release injectable suspension to provide analgesia for laboratory animals
Pseudo MarkETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) ONE POINT THREE MG/ML
Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"XR" AND "(BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 11, 2017
Primary Code005
First Use Anywhere DateThursday, August 6, 2020
First Use In Commerce DateThursday, August 6, 2020

Trademark Owner History

Party NameFIDELIS ANIMAL HEALTH, INC.
Party Type32 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressNORTH BRUNSWICK, NJ 08902
Party NameFIDELIS PHARMACEUTICALS, INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressNORTH BRUNSWICK, NJ 08902
Party NameFIDELIS PHARMACEUTICALS LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressNorth Brunswick, NJ 08902
Party NameFIDELIS PHARMACEUTICALS LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNorth Brunswick, NJ 08902
Party NameFIDELIS PHARMACEUTICALS LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew Rochelle, NY 10801

Trademark Events

Event DateEvent Description
Wednesday, June 22, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, May 19, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, September 22, 2020REGISTERED-PRINCIPAL REGISTER
Friday, August 21, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, August 20, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 19, 2020STATEMENT OF USE PROCESSING COMPLETE
Monday, August 17, 2020USE AMENDMENT FILED
Monday, August 17, 2020TEAS STATEMENT OF USE RECEIVED
Tuesday, July 7, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 7, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 7, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, April 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 2, 2020SOU EXTENSION 3 GRANTED
Thursday, April 2, 2020SOU EXTENSION 3 FILED
Thursday, April 2, 2020TEAS EXTENSION RECEIVED
Saturday, November 2, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 31, 2019SOU EXTENSION 2 GRANTED
Thursday, October 31, 2019SOU EXTENSION 2 FILED
Thursday, October 31, 2019TEAS EXTENSION RECEIVED
Tuesday, June 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2019SOU EXTENSION 1 GRANTED
Monday, May 13, 2019SOU EXTENSION 1 FILED
Monday, June 17, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 14, 2019NOTICE OF REVIVAL - E-MAILED
Tuesday, May 14, 2019EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, May 14, 2019PETITION TO REVIVE-GRANTED
Tuesday, May 14, 2019TEAS PETITION TO REVIVE RECEIVED
Wednesday, November 28, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 28, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 28, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 28, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 13, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 18, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 18, 2018PUBLISHED FOR OPPOSITION
Wednesday, August 29, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 16, 2018ASSIGNED TO LIE
Saturday, August 4, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, August 4, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, August 4, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, August 4, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 7, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 7, 2018NON-FINAL ACTION E-MAILED
Monday, May 7, 2018NON-FINAL ACTION WRITTEN
Wednesday, April 11, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 11, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 11, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 14, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 14, 2018NON-FINAL ACTION E-MAILED
Wednesday, March 14, 2018NON-FINAL ACTION WRITTEN
Tuesday, March 13, 2018ASSIGNED TO EXAMINER
Tuesday, December 12, 2017NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, December 11, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, December 4, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

injectable suspension release extended buprenorphine ethiqa provide analgesia laboratory animals preparations namely